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Abstract
Multilocus sequence typing of an almost complete collection of
invasive group B streptococcus (GBS) strains from infants in
Norway, conducted in 2006–2007, revealed 27 sequence types
(ST), of which 23 clustered into ﬁve clonal complexes. The case
fatality rate of invasive GBS disease in infants was 16/98 (16.3%).
Type V strains were predominant among strains resistant to
erythromycin and clindamycin (11/18; 61.1%). All type V strains
from fatal cases (5/16) were ST1, resistant to erythromycin and
clindamycin, and belonged to three pulsed-ﬁeld gel electrophore-
sis-clusters. Further analysis of virulence characteristics of these
apparently highly virulent subtypes of type V, ST1 GBS strains is
warranted.
Keywords: Antibiotic susceptibility, early onset disease, invasive
GBS disease, multilocus sequence typing, pulsed-ﬁeld gel electro-
phoresis
Original Submission: 4 July 2008; Revised Submission:
28 August 2008; Accepted: 30 October 2008
Editor: P. Tassios
Article published online: 15 May 2009
Clin Microbiol Infect 2009; 15: 1182–1185
10.1111/j.1469-0691.2009.02789.x
Corresponding author and reprint requests: H. Bergseng, LBK,
Laboratory centre, Erling Skjalgssons gt.1, 7006 Trondheim, Norway
E-mail: hakon.bergseng@ntnu.no
The present study aimed to characterize isolates from infants
with invasive group B streptococcus (GBS) disease in
Norway, in 2006 and 2007, and to compare the population
structure of GBS with previous studies. We also aimed to
investigate whether phylogenetic lineages were associated
with speciﬁc characteristics such as susceptibility to erythro-
mycin and clindamycin, geographic origin, early or late onset
GBS disease, and lethality.
Data on invasive GBS disease in infants were obtained
from the Norwegian Surveillance System for Communicable
Diseases, to which all laboratory conﬁrmed cases of invasive
GBS disease are compulsorily notiﬁable. GBS strains from
infants with invasive GBS disease were characterized at the
national reference laboratory for GBS at St Olavs University
Hospital.
Multilocus sequence typing (MLST) was carried out as
described previously [1]. Nucleotide sequences of new alleles
and new sequence types (STs) identiﬁed in the present study
are available at: http://sagalactiae.mlst.net. Strains were
grouped into clonal complexes (CC) using eBURST [2]. The
term singleton ST refers to STs that did not cluster into a
CC.
Capsular typing and detection of genes encoding surface
proteins were performed by PCR [3–5]. Type V strains were
also analysed by pulsed-ﬁeld gel electrophoresis (PFGE) using
SmaI [6]. Cluster analysis of PFGE fragment patterns was
done using Dice coefﬁcients at 1.2% tolerance and 0.5%
optimization, and a dendrogram was constructed with the
unweighted pair-group method with arithmetic mean using
Bionumerics, version 5.10 (Applied Maths, Sint-Martens-
Latem, Belgium). Signiﬁcant clusters were identiﬁed by the
cluster cut-off method (Bionumerics).
All GBS isolates were tested for susceptibility to erythro-
mycin and clindamycin using the disc diffusion method. Eryth-
romycin resistant, clindamycin sensitive strains were tested
for inducible clindamycin resistance. The methods used were
recommended by the Norwegian Working Group on Antibi-
otics (http://www.antibiotikaresistens.no) and the Swedish
Reference Group for Antibiotics (http://www.srga.org) and
the results were interpreted according to their criteria.
Categorical data were compared by Fisher’s exact test.
Among 116 959 live births in Norway during 2006 and
2007, 56 cases (0.48/1000 live births) of invasive GBS disease
in infants <7 days of age (early onset disease; EOD) and 42
cases (0.36/1000) in infants ‡7 days of age (late onset dis-
ease; LOD) were reported to the Norwegian Surveillance
System for Communicable Diseases. The case fatality rate
was 16 out of 98 (16.3%). Strains from 96 of the 98 infants
were available for phenotypic and genotypic characterization.
The distribution of capsular types and genes encoding sur-
face proteins is shown in Table 1. Several genes were related
to speciﬁc capsular types (rib in type III, alp2/3 in V and bca,
bac in Ib and II).
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Using MLST, 27 STs were identiﬁed, 11 of which had not
been previously reported (Table 1). Using eBURST analysis,
23 STs were distributed into ﬁve different CCs (CC17, CC1,
CC19, CC358 and CC23), whereas four STs were single-
tons. The new ST358 was classiﬁed as founder of CC358,
which included seven STs. Fatal cases were found within all
ﬁve CCs. Interestingly, only one of these strains belonged to
CC17, which comprised the largest number of strains in the
present study. There was no signiﬁcant difference in the dis-
tribution of CCs between EOD and LOD (Table 1), nor in
the geographic origin of the strains (data not shown). The
proportion of strains belonging to ST17 was higher in LOD
than in EOD (13/42, 31% vs. 10/54, 19%) (Table 1), but the
association to LOD was not signiﬁcant.
Resistance to erythromycin was detected in 18 out of 96
strains (18.8%), whereas 19 out of 96 (19.8%) were resistant
to clindamycin. Inducible clindamycin resistance was
observed in ten of the latter strains. Resistance was most
frequent in type V strains (11/18 strains; 61.1%). All strains
with resistance to erythromycin and/or clindamycin, except
one strain in CC358, were conﬁned to two CCs (CC1 and
CC19). None of the CC17 and CC23 strains showed resis-
tance to erythromycin or clindamycin (Table 1). Lethal cases
were observed in ﬁve out of 18 infants infected with type V
(Table 1). In addition, the frequent erythromycin and/or clin-
damycin resistance in type V might suggest a possible clonal
outbreak. PFGE was performed on all type V strains (Fig. 1).
Overall, ten PFGE patterns belonging to four different clus-
ters were identiﬁed among the18 type V strains. The ﬁve
strains from fatal cases were found within three of the PFGE
clusters. Strains with inducible clindamycin resistance were
conﬁned to two clusters.
Except for the new CC358, the most prevalent CCs
among the GBS strains in the present study were similar to
CCs previously reported in invasive and colonizing strains
from different geographic areas [7–9]. The distribution of
capsular types in relation to CCs was also similar to that
reported in previous studies [7–9].
Previously, it has been shown that ST17 corresponds to
subtype III-2 and that it is associated with LOD [10,11];
TABLE 1. Distribution of clonal
complexes (CCs) in invasive group
B streptococcus strains from
infants in Norway, 2006 and 2007
CC and
ST
Number
of strains
n = 96
Capsular
type
Gene for
surface
protein
Resistant to
erythromycin
n = 18
Resistant to
clindamycin
n = 19 (inducible
clindamycin
resistance n = 10)
Early
onset
disease
n = 54
Late
onset
disease
n = 42
Fatal
cases
n = 16
CC358a
8 3 Ib bca,bac 0 0 (0) 1 2 –
10 2 Ib bca,bac 0 0 (0) 1 1 1
358a 1 II bca,bac 0 0 (0) 1 0 –
9 1 Ib bca,bac 0 0 (0) 1 0 1
350a 1 II bca,bac 1 1 (0) 1 0 –
46 1 Ia epsilon 0 0 (0) 1 0 –
362a 1 Ib bca,bac 0 0 (0) 1 0 –
CC17
17 23 III rib 0 0 (0) 10 13 –
359a 2 III rib 0 0 (0) 1 1 –
360a 1 III rib 0 0 (0) 1 0 –
357a 1 III rib 0 0 (0) 0 1 –
48 2 III rib 0 0 (0) 1 1 1
95 1 III rib 0 0 (0) 1 0 –
CC1 9
19 1 II rib 0 0 (0) 1 0 –
19 10 III rib 2 3 (1) 7 3 2
27 3 III rib 1 1 (1) 2 1 1
106 2 III rib 2 2 (2) 0 2 –
351a 1 III rib 1 1 (1) 1 0 –
CC1
1 16 V alp2/3b 11 11 (5) 9 7 5
1 1 VI bca 0 0 1 0 –
2 1 II epsilon 0 0 1 0 1
196 7 IV epsilon 0 0 6 1 1
349a 1 V alp2/3b 0 0 0 1 –
CC23
23 6 Ia epsilon 0 0 2 4 2
23 1 III rib 0 0 0 1 –
52 1 Ia epsilon 0 0 0 1 –
Singletons
361a 1 Ib bca,bac 0 0 0 1 –
345a 1 V alp2/3b 0 0 1 0 –
24 2 Ia bca 0 0 1 1 1
363a 1 Ib bca,bac 0 0 1 0 –
ST, sequence type.
aNot previously reported.
bThe genes alp2 and alp3 were not tested for separately.
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however, the possible association with LOD observed in the
present study was not signiﬁcant (Table 1).
The case fatality rate in 2006 and 2007 was signiﬁcantly
higher than that observed in the period 1996–2005 [16/98
(16.3%) vs. 25/384 (6.5%) (p 0.02)] [12]. This appears to
coincide with an increased resistance to erythromycin and
clindamycin that has been observed in recent years and
might indicate the emergence of more virulent GBS strains
in Norway [12].
The high proportion of resistant type V strains in the
present study is consistent with other studies [11,13]. By
visually comparing published gel images, one is led to infer
similarities between a major PFGE proﬁle of type V strains in
the present study and the most common PFGE pattern of
type V in the USA and Germany [13–15]. However, a direct
comparison in the laboratory remains to be performed.
Assessed by MLST, the present population structure of
invasive GBS strains in Norway is not very different from
that reported in other countries over the last 10 years. ST1,
type V strains that showed resistance to erythromycin and/
or clindamycin, and were frequent among fatal cases, were
distributed into three cluster groups by PFGE. Further analy-
sis of the virulence characteristics of these apparently highly
virulent subtypes of strains is warranted.
Transparency Declaration
The authors would like to thank the Norwegian Women’s
Public Health Association for providing ﬁnancial support for
this study. The authors do not have any commercial or
other associations that constitute dual or conﬂicting
interests.
References
1. Jones N, Bohnsack JF, Takahashi S et al. Multilocus sequence typing
system for group B streptococcus. J Clin Microbiol 2003; 41: 2530–
2536.
2. Feil EJ, Li BC, Aanensen DM et al. eBURST: inferring patterns of evo-
lutionary descent among clusters of related bacterial genotypes from
multilocus sequence typing data. J Bacteriol 2004; 186: 1518–30.
3. Zeng X, Kong F, Morgan J et al. Evaluation of a multiplex PCR-based
reverse line blot-hybridization assay for identiﬁcation of serotype and
surface protein antigens of Streptococcus agalactiae. J Clin Microbiol
2006; 44: 3822–3825.
4. Creti R, Fabretti F, Oreﬁci G et al. Multiplex PCR assay for direct
identiﬁcation of group B streptococcal alpha-protein-like protein
genes. J Clin Microbiol 2004; 42: 1326–1329.
5. Kong F, Gowan S, Martin D et al. Serotype identiﬁcation of group B
streptococci by PCR and sequencing. J Clin Microbiol 2002; 40: 216–226.
6. Skjaervold NK, Bergh K, Bevanger L. Distribution of PFGE types of
invasive Norwegian group B streptococci in relation to serotypes.
Indian J Med Res 2004; 119 (suppl): 201–204.
7. Bisharat N, Jones N, Marchaim D et al. Population structure of group
B streptococcus from a low-incidence region for invasive neonatal
disease. Microbiology 2005; 151:1875–1881.
8. Luan SL, Granlund M, Sellin M et al. Multilocus sequence typing of
Swedish invasive group B streptococcus isolates indicates a neonatally
associated genetic lineage and capsule switching. J Clin Microbiol 2005;
43: 3727–3733.
9. Bohnsack JF, Whiting A, Gottschalk M et al. Population structure of
invasive and colonizing strains of Streptococcus agalactiae from neo-
nates of six US Academic Centers from 1995 to 1999. J Clin Microbiol
2008; 46: 1285–1291.
10. Sun Y, Kong F, Zhao Z et al. Comparison of a 3-set genotyping sys-
tem with multilocus sequence typing for Streptococcus agalactiae
(group B streptococcus). J Clin Microbiol 2005; 43: 4704–4707.
11. Zhao Z, Kong F, Zeng X et al. Distribution of genotypes and antibi-
otic resistance genes among invasive Streptococcus agalactiae (group B
streptococcus) isolates from Australasian patients belonging to differ-
ent age groups. Clin Microbiol Infect 2008; 14: 260–267.
12. Bergseng H, Rygg M, Bevanger L et al. Invasive group B streptococcus
(GBS) disease in Norway 1996–2006. Eur J Clin Microbiol Infect Dis
2008; 27: 1193–1199.
10
0
9080 MLST
1
1
1
1
1
1
1
1
1
345
1
1
1
1
1
1
349
1
S/R/IR
IR
IR
IR
IR
IR
R
S
S
S
S
R
R
R
R
R
S
S
S
EOD/LOD
LOD
LOD
LOD
EOD
LOD
EOD
EOD
EOD
EOD
EOD
LOD
LOD
EOD
LOD
EOD
EOD
LOD
EOD
Fatal case
+
+
+
+
+
FIG. 1. Analysis of invasive type V
group B streptococcus strains from
infants in Norway 2006–2007. The
strains were analysed with pulsed-ﬁeld
gel electrophoresis, multilocus sequence
typing (MLST), and for susceptibility to
erythromycin and clindamycin (S, sensi-
tive; R, resistant; IR, inducible resis-
tance). The association to fatality and
onset of disease is indicated (early
onset, EOD; late onset disease, LOD).
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Abstract
Rabies remains endemic in many regions of Turkey. As a
consequence, humans are at risk of this fatal disease through
encounters with rabid animals. The present study describes four
recent cases of rabies in humans. Subsequent phylogenetic analy-
sis of the rabies virus isolates obtained from each case demon-
strates the distinct geographical distribution of rabies virus
variants within Turkey. The study suggests that rabies virus
translocation has occurred across Turkey and might be the
source of the emergence of a genetically similar variant in the
Golan Heights region on the Israeli/Syrian border in 2004.
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Rabies is one of the major zoonotic diseases in Turkey. The
virus is enzootic in many areas of Turkey, with dogs being
the principal reservoir and vector, bringing humans into
contact with the virus [1]. The presence of the disease in
dogs and, in some areas, in wildlife, represents a continuing
threat to public health and causes economic losses, especially
in domestic livestock [2]. Within Turkey, veterinary control
and research institutes are responsible for diagnosis of the
disease (in animals) at sites distributed throughout the coun-
try (Adana, Elazıg, Erzurum, Etlik-Central-Ankara, Konya,
Istanbul, Izmir, Samsun). The Ministry of Agriculture and
Rural Affairs reports to OIE and WHO regularly. Reported
cases in animals between 2002 and 2006 were 217, 156, 111,
193 and 210, respectively, suggesting the persistence of the
disease (http://www.who-rabies-bulletin.org). The Ministry of
Health is responsible for diagnosis of cases of rabies in
humans and for subsequent reporting to WHO.
In the present study, we have investigated four recent
cases of rabies in humans (Table 1). This is the ﬁrst report
of ante-mortem rabies diagnosis in Turkey; cases TR149 and
TR40 tested positive according to the direct ﬂuorescent
antibody test (dFAT) on corneal smears and RT-PCR on
saliva and eye swabs. It is also the ﬁrst genetic analysis of
rabies viruses of human origin from Turkey.
The ﬁrst case (TR33) occurred in Kilis province in 2002, the
second (TR149) in Agri province in 2004, the third (TR40) in
Adana province in 2006, and the fourth (TR3) in Aydin
province in 2006. For each case, brain tissue specimens, saliva,
corneal impressions, swabs from the eyes, and cerebrospinal
ﬂuid were collected. Samples were shipped to the National
Reference Laboratory for rabies at the Etlik Central Veterinary
Control and Research Institute (ECVCRI) for further investi-
gation. Infection with rabies was conﬁrmed by dFAT. The test
was performed using a commercial conjugate (Fujirebio, Mal-
vern, USA) as described previously [3]. The mouse inoculation
test was undertaken using standard protocols [4]. Total RNA
was extracted directly from samples by the TRIzol method
according to the manufacturer’s instructions (TRI Reagent;
Sigma-Aldrich ChemieGmbH, Germany). Heminested RT-PCR
was performed as described by Heaton et al. [5]. The products
of positive PCR ampliﬁcation were puriﬁed with a commercial
kit (QIAquick gel extraction KIT, QiagenGmbH, Germany)
and were sequenced using the BigDye Terminator v3.1 cycle
sequencing kit (Applied Biosystems, Foster City, CA, USA)
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